-
-
-
-
-
-
-
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2b CORAL Trial
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)
-
-
-
-
-
-
-
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c
-
-
-
-
-
-
-
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
-
1,199,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

